Department of Medicine, Inpatient Clinician Educator Service, Harvard Medical School, Boston, Massachusetts, USA.
J Hosp Med. 2010 Oct;5(8):477-85. doi: 10.1002/jhm.849.
Medication errors and adverse events caused by them are common during and after a hospitalization. The impact of these events on patient welfare and the financial burden, both to the patient and the healthcare system, are significant. In 2005, The Joint Commission put forth medication reconciliation as National Patient Safety Goal (NPSG) No. 8 in an effort to minimize adverse events caused during these types of care transitions. However, the meaningful and systematic implementation of medication reconciliation, as expressed through NPSG No. 8, proved to be extraordinarily difficult for healthcare institutions around the country. Given the importance of accurate and complete medication reconciliation for patient safety occurring across the continuum of care, the Society of Hospital Medicine convened a stakeholder conference in 2009 to begin to identify and address: (1) barriers to implementation; (2) opportunities to identify best practices surrounding medication reconciliation; (3) the role of partnerships among traditional healthcare sites and nonclinical and other community-based organizations; and (4) metrics for measuring the processes involved in medication reconciliation and their impact on preventing harm to patients. The focus of the conference was oriented toward medication reconciliation for a hospitalized patient population; however, many of the themes and concepts derived would also apply to other care settings. This paper highlights the key domains needing to be addressed and suggests first steps toward doing so. An overarching principle derived at the conference is that medication reconciliation should not be viewed as an accreditation function. It must, first and foremost, be recognized as an important element of patient safety. From this principle, the participants identified ten key areas requiring further attention in order to move medication reconciliation toward this focus. 1 There is need for a uniformly acceptable and accepted definition of what constitutes a medication and what processes are encompassed by reconciliation. Clarifying these terms is critical to ensuring more uniform impact of medication reconciliation. 2 The varying roles of the multidisciplinary participants in the reconciliation process must be clearly defined. These role definitions should include those of the patient and family/caregiver and must occur locally, taking into account the need for flexibility in design given the varying structures and resources at healthcare sites. 3 Measures of the reconciliation processes must be clinically meaningful (i.e., of defined benefit to the patient) and derived through consultation with stakeholder groups. Those measures to be reported for national benchmarking and accreditation should be limited in number and clinically meaningful. 4 While a comprehensive reconciliation system is needed across the continuum of care, a phased approach to implementation, allowing it to start slowly and be tailored to local organizational structures and work flows, will increase the chances of successful organizational uptake. 5 Developing mechanisms for prospectively and proactively identifying patients at risk for medication-related adverse events and failed reconciliation is needed. Such an alert system would help maintain vigilance toward these patient safety issues and help focus additional resources on high risk patients. 6 Given the diversity in medication reconciliation practices, research aimed at identifying effective processes is important and should be funded with national resources. Funding should include varying sites of care (e.g., urban and rural, academic and nonacademic, etc.). 7 Strategies for medication reconciliation-both successes and key lessons learned from unsuccessful efforts-should be widely disseminated. 8 A personal health record that is integrated and easily transferable between sites of care is needed to facilitate successful medication reconciliation. 9 Partnerships between healthcare organizations and community-based organizations create opportunities to reinforce medication safety principles outside the traditional clinician-patient relationship. Leveraging the influence of these organizations and other social networking platforms may augment population-based understanding of their importance and role in medication safety. 10 Aligning healthcare payment structures with medication safety goals is critical to ensure allocation of adequate resources to design and implement effective medication reconciliation processes. Medication reconciliation is complex and made more complicated by the disjointed nature of the American healthcare system. Addressing these ten points with an overarching goal of focusing on patient safety rather than accreditation should result in improvements in medication reconciliation and the health of patients.
在住院期间和之后,药物错误和由此引起的不良事件很常见。这些事件对患者福利和患者及医疗体系的经济负担都有重大影响。2005 年,联合委员会将用药核对作为国家患者安全目标(NPSG)第 8 项,努力减少这些类型的护理过渡期间发生的不良事件。然而,全国各地的医疗机构在实现 NPSG 第 8 项所表达的有意义和系统的用药核对实施方面遇到了巨大困难。鉴于准确和完整的用药核对对整个医疗保健连续体中患者安全的重要性,医院医学学会于 2009 年召开了利益相关者会议,开始确定和解决以下问题:(1)实施的障碍;(2)确定围绕用药核对的最佳实践的机会;(3)传统医疗场所与非临床和其他社区组织之间伙伴关系的作用;(4)衡量与用药核对相关的流程及其对预防患者伤害的影响的指标。会议的重点是针对住院患者群体的用药核对;然而,从中得出的许多主题和概念也适用于其他护理环境。本文重点介绍需要解决的关键领域,并提出实现这一目标的初步步骤。会议得出的一个总体原则是,用药核对不应被视为认证功能。它必须首先被视为患者安全的一个重要组成部分。从这一原则出发,与会者确定了十个需要进一步关注的关键领域,以便将用药核对工作重点转移到这一目标上来。1 需要一个统一接受和接受的定义,即什么构成药物,什么过程包括核对。澄清这些术语对于确保用药核对的影响更加统一至关重要。2 必须明确界定多学科参与者在核对过程中的不同角色。这些角色定义应包括患者和家属/照顾者的角色,并且必须在当地进行,同时考虑到设计的灵活性,因为医疗保健场所的结构和资源各不相同。3 核对流程的衡量标准必须具有临床意义(即对患者有明确的益处),并通过与利益相关者团体协商得出。那些要报告用于国家基准测试和认证的措施应数量有限且具有临床意义。4 虽然需要在整个医疗保健连续体中建立全面的核对系统,但分阶段实施的方法,允许它缓慢启动并根据当地的组织结构和工作流程进行调整,将增加成功组织采用的机会。5 需要开发前瞻性和主动识别有药物相关不良事件和核对失败风险的患者的机制。这样的警报系统将有助于保持对这些患者安全问题的警惕,并有助于将额外的资源集中在高风险患者身上。6 鉴于用药核对实践的多样性,确定有效流程的研究很重要,应该用国家资源来资助。资金应包括不同的护理场所(如城市和农村、学术和非学术等)。7 应广泛传播用药核对的成功策略和从不成功努力中吸取的关键经验教训。8 需要一个集成的、在护理场所之间易于传输的个人健康记录,以促进成功的用药核对。9 医疗保健组织与社区组织之间的伙伴关系为强化传统医患关系之外的药物安全原则创造了机会。利用这些组织和其他社交网络平台的影响力,可以增强公众对其重要性和在药物安全中的作用的认识。10 调整医疗保健支付结构与药物安全目标一致,对于确保为设计和实施有效的药物核对流程分配足够的资源至关重要。药物核对很复杂,而且由于美国医疗体系的不连贯性质而变得更加复杂。以关注患者安全而不是认证为总体目标来解决这十个问题,应该会改善药物核对和患者的健康状况。